RNA virus infection is sensed in the cytoplasm by the retinoic acid-inducible gene I (RIG-I)-like receptors. These proteins signal through the host adaptor protein MAVS to trigger the antiviral innate immune response. Here, we describe how MAVS subcellular localization impacts its function and the regulation underlying MAVS signaling. We propose a model to describe how the coordination of MAVS functions at the interface between the mitochondria and the mitochondrion-associated endoplasmic reticulum (ER) membrane programs antiviral signaling.
T
he host signaling adaptor protein MAVS is essential to drive antiviral innate immunity in response to RNA virus infection (1) . Known protein domains of MAVS include a caspase activation and recruitment domain (CARD) at the N terminus, a proline-rich region, and a C-terminal membrane-targeting transmembrane domain (Fig. 1) . MAVS also contains three tumor necrosis factor receptor-associated factor (TRAF)-interacting motifs (TIMs), two in the proline-rich region and one near the transmembrane domain (Fig. 1 ). MAVS is a classical tail-anchored membrane protein, and this C-terminal transmembrane anchor localizes MAVS to a diverse set of membranes, including at peroxisomes and mitochondria, as well as to a subdomain of the endoplasmic reticulum (ER) called the mitochondrion-associated membrane (MAM) (2) (3) (4) . The regulatory factors that mediate these different subcellular localizations of MAVS are completely unknown, and a simple analysis of the transmembrane domain of MAVS does not reveal any obvious targeting signals. We hypothesize that MAVS targeting of specific lipids and host proteins contributes to both its localization and antiviral signaling function. In fact, specific protein-protein interactions within the transmembrane domain of MAVS with host proteins could contribute to the proper sorting and subcellular targeting of MAVS, as they have for other membrane-associated proteins (5) . As MAVS must be anchored in the membrane to drive antiviral signaling (4), these interactions with host membranes must play an important regulatory role in MAVS innate immune signaling.
INITIATION OF THE MAVS ANTIVIRAL IMMUNE RESPONSE
MAVS-dependent antiviral signaling initiates after the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) RIG-I and melanoma differentiation-associated protein 5 (MDA5) sense viral RNA in the infected cell. This initiation of signaling drives interactions between the RLRs, MAVS, and corresponding regulatory proteins and organelles. These RLRs become activated upon binding to viral RNA pathogen-associated molecular patterns (PAMPs). For RIG-I, these PAMPs include double-stranded RNA (dsRNA) with either a 5= diphosphate or 5= triphosphate (reviewed in reference 6). Activation of these RLRs induces signals that drive their interaction with MAVS through CARDs present in both the RLRs and MAVS. In particular, RIG-I activation during RNA virus sensing is facilitated by the actions of the E3 ubiquitin ligases, Riplet and TRIM25 (tripartite motif-containing protein 25), which catalyze K63 ubiquitin linkages on RIG-I for full activation (6) . Following this ubiquitin-mediated activation, RIG-I oligomerizes and forms a complex with TRIM25 and the molecular chaperone 14-3-3ε (7, 8) . This complex, termed a "translocon," relocalizes from the cytoplasm to intracellular membranes, including the MAM, for interaction with MAVS (3, 7).
CONTROLS FOR MAVS EXPRESSION AND FUNCTION REGULATE THE ANTIVIRAL RESPONSE
MAVS is not an interferon (IFN)-stimulated gene, and so its expression is not directly regulated by IFN. Instead, both the expression and function of MAVS are regulated by other mechanisms at the transcriptional, posttranscriptional, and posttranslational levels. At the transcriptional level, MAVS mRNA levels are regulated in a negative-feedback loop by reactive oxygen species (ROS) generated during the antiviral response (9) . The MAVS gene also encodes a number of splice variants that have been proposed to negatively regulate MAVS signaling (10) . At the posttranscriptional level, translation of MAVS can be initiated by two different translation start sites, including one that uses an internal methionine to begin translation (11) (Fig. 1 ). This alternative internal translation of MAVS, likely mediated by upstream open reading frame skipping, results in expression of a shorter isoform of MAVS of 398 amino acids that lacks the CARD domain (11) . While this isoform has previously been termed "miniMAVS" (11), we refer to it here as short-MAVS (sMAVS), as "miniMAVS" was also used previously to describe a MAVS containing only a CARD and transmembrane domain (4) . Although it has been proposed that sMAVS functions as a negative regulator of the antiviral response, there is evidence in the literature supporting the hypothesis that sMAVS is actually positively regulating antiviral signaling. Two studies have shown that during RNA virus infection, expression of full-length MAVS (FL-MAVS) diminishes over time, while expression of the sMAVS remains constant (11, 12) . In addition, during RNA virus infection, the loss of FL-MAVS expression immediately precedes phosphorylation of interferon regulatory factor 3 (IRF3), a transcription factor that induces antiviral gene expression, suggesting that this loss actually positively regulates antiviral signaling (12) . What causes the loss of FL-MAVS expression? During RNA virus infection, MAVS is polyubiquitinated (K48) on lysine residues 7 and 10 at the amino terminus, resulting in proteasome-mediated degradation of FL-MAVS (12) . However, this K48-linked ubiquitination does not affect sMAVS expression because sMAVS does not contain these amino acid residues (12) . This ubiquitination of MAVS appears to be catalyzed by TRIM25 (which also mediates K63 ubiquitination of RIG-I) and as part of the RIG-I translocon would be expected to be in the proximity of MAVS to facilitate this ubiquitination.
Other direct posttranslational modifications of MAVS that regulate antiviral signaling include phosphorylation and ubiquitination at several sites in the protein (Fig. 1) . Negative regulators of MAVS include E3 ubiquitin ligases (e.g., Ring finger protein 5 [RNF5], RNF125) that catalyze K48 ubiquitination of MAVS leading to MAVS degradation by the proteasome, as well as kinases (e.g., polo-like kinase 1 [PLK1]) that phosphorylate MAVS to prevent signaling factor recruitment (13) . Posttranslational modifications of MAVS that positively regulate antiviral signaling include the K48 degradative ubiquitination described above which results in proteasome-dependent degradation of the FL-MAVS but not sMAVS. In addition, MAVS phosphorylation at other sites positively regulates MAVS signal propagation ( Fig. 1) (14) . Compared to upstream activation of MAVS, relatively little is known about the molecular mechanisms of how MAVS signals are transduced.
HOW DOES MAVS SUBCELLULAR LOCALIZATION REGULATE ANTIVIRAL IMMUNITY?
It has been proposed that the differential localization of MAVS to peroxisomes and mitochondria drives different antiviral signaling programs. In this model, mitochondrial MAVS signals the induction of beta interferon (IFN-␤), a type I IFN, while peroxisomal MAVS signals the induction of the type III IFNs (15) . This hypothesis that differential localization of MAVS drives different antiviral signaling programs is an attractive one. Indeed, MAVS does signal to induce both type I and type III IFNs in response to virus infection, including hepatitis C virus (HCV) (15, 16) . However, MAVS signaling is likely more complicated than differential localization simply regulating differential activation of transcriptional responses. In the original study that revealed that MAVS on different organelles drove different antiviral responses, the last 40 amino acids of MAVS were replaced with organelle-specific membrane-targeting domains (2). However, there is no formal way to prove that these heterologous membrane-targeting domains affect all of the normal downstream signaling capacities of MAVS. For example, these heterologous domains could mediate different protein-protein or lipid interactions through their transmembrane domains, which could subsequently drive different signaling responses. Indeed, a recent study that used these heterologous organelle-specific targeting domains to relocalize MAVS found that these relocalized MAVS proteins lost their ability to induce apoptosis, which is also regulated by MAVS (17) . While it is possible that MAVS at each of these locations does have an organellespecific antiviral function, our previous work has revealed that under conditions where MAVS is not overexpressed, the three known intracellular membranes that contain MAVS (MAM, mitochondria, and peroxisomes) all interact with each other in signaling "synapses" during activation of the RIG-I pathway (3), suggesting that signaling from these organelles is coregulated.
The localization of MAVS to the MAM-mitochondrial interface strongly suggests that this localization is important for its antiviral signaling function. MAM and mitochondria are physically tethered to each other by proteins that link these organelles, including mitofusin 2 (MFN2), as shown in Fig. 2 . Interestingly, MFN2 is known to interact with MAVS and at a resting state MFN2 prevents MAVS oligomerization, implicating MAM-mitochondrial contacts in antiviral signaling regulation (3, 9) . The MAM is best known for its role in compartmentalizing cellular metabolic and apoptotic programs (18) . In fact, these metabolic programs include candidate and proven regulators of antiviral innate immune signaling. For example, mitochondrial dynamics and morphology, mitochondrial ROS, and mitochondrial membrane potential (⌬ m ) are all physiologic regulators of antiviral immunity (reviewed in reference 9). Compared to other intracellular membranes, the MAM is enriched in cholesterol and neutral lipids, and so the specific lipid content of the MAM may also play a role in coordinating the MAVS-dependent antiviral response.
TARGETING OF MAVS ANTIVIRAL SIGNALING BY HCV
Many viruses have strategies to evade antiviral immunity. In particular, the HCV NS3-NS4A protease complex inactivates MAVS signaling of antiviral immunity by cleaving MAVS at cysteine 508, directly upstream of the MAVS membrane-targeting domain (19) (Fig. 1) . This cleavage releases MAVS from intracellular membranes preventing antiviral signaling. Similar to MAVS, NS3-NS4A is also mem- brane anchored and localized to the same subcellular organelles as MAVS, including peroxisomes, mitochondria, and MAM contact sites with these organelles (3). Importantly, NS3-NS4A does not cleave MAVS at the mitochondria; instead, it cleaves MAVS at the MAM (3). While specific peroxisomal cleavage of MAVS by NS3-NS4A has not been tested, the finding that a portion of NS3-NS4A is localized to peroxisomes suggests that it could cleave peroxisomal MAVS. Indeed, NS3-NS4A does block antiviral induction of both type I and type III IFNs (16, 20) . Why would the HCV NS3-NS4A protease cleave MAVS on the MAM but not the mitochondria? We propose that interactions between the mitochondrion-and MAMlocalized MAVS facilitate regulated downstream antiviral signaling. In this way, NS3-NS4A cleavage of the MAM-MAVS may prevent the full propagation of this antiviral signaling during HCV infection.
MODEL OF MAVS ANTIVIRAL SIGNALING
On the basis of the known controls for MAVS expression and function, the studies of MAVS localization, and known organelle interactions during the antiviral response, we propose a model for MAVS antiviral signaling at the MAM-mitochondrial interface (Fig. 2) . While we did not focus on peroxisomes in this model, the literature strongly supports their role in the antiviral innate immune response (2, 3, 15) . In this model, MAVS is held in an inactive state by proteins at the MAM-mitochondrial interface, such as MFN2 or other known negative regulators of MAVS localized to the mitochondria. Upon RIG-I sensing of viral RNA in the cytosol, RIG-I oligomerization, and RIG-I translocation to the MAM, MAVS becomes activated by CARD-CARD interactions between MAVS and RIG-I. This interaction results in MAVS oligomerization, both through the CARD and transmembrane domain, for recruitment of downstream signaling factors to form a MAVS signaling complex. The translocation of RIG-I to the MAM brings TRIM25 in close proximity to MAVS for ubiquitination of MAVS (K48, red) at the CARD to catalyze proteasome-mediated degradation of FL-MAVS, while sMAVS is not degraded. We propose that sMAVS is then released from the regulatory complex at the MAM-mitochondrial interface to promote downstream signaling of antiviral immunity. In support of this model, MAVS with a mutation in the transmembrane domain that relocalizes MAVS to the ER but maintains MAVS dimerization is constitutively active (21) . Phosphorylation and K63-linked ubiquitination of MAVS, as well as rearrangement of intracellular membranes, including the Golgi membranes, are required for full signaling factor recruitment to MAVS and transcriptional induction of antiviral immunity (22, 23) . Ultimately, all of these diverse regulatory controls of MAVS reveal that multiple, concurrent, and dynamic protein interactions work together to orchestrate antiviral immunity.
